CCL5 as a potential immunotherapeutic target in triple-negative breast cancer

Cellular and Molecular Immunology

Volumn 10, Issue 4, 2013, Pages 303-310

  Lv, Dandan ^a   Zhang, Yan ^b   Kim, Ha Jeong ^b   Zhang, Lixing ^a   Ma, Xiaojing ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CCL5; immunotherapy; myeloid derived suppressor cell; triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CCL5 ANTIBODY; CCL5 INHIBITOR; CD5 ANTIGEN; CHEMOTAXIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGESTERONE RECEPTOR; RANTES; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

BONE MARROW CELL; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CCL5 GENE; DRUG TARGETING; GENE EXPRESSION REGULATION; HEMATOPOIETIC CELL; HUMAN; INFLAMMATORY BREAST CANCER; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SUPPRESSOR CELL; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHEMOKINE CCL5; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOTHERAPY; MODELS, ANIMAL; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE;

ANIMALIA;

EID: 84878802497     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2012.69     Document Type: Review

References (94)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867. (Pubitemid 36019639)
2. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-1837. (Pubitemid 34408510)
3. Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C et al. CCR5 expression influences the progression of human breast cancerinap53- dependentmanner. J Exp Med 2003; 198: 1381-1389. (Pubitemid 37392483)
4. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM et al. Ahuman Tcell-specificmoleculeisamemberofanewgenefamily. JImmunol 1988; 141: 1018-1025.
5. Song A, Chen YF, Thamatrakoln K, Storm TA, Krensky AM. RFLAT-1:a new zinc finger transcription factor that activates RANTES gene expression in T lymphocytes. Immunity 1999; 10: 93-103. (Pubitemid 29077387)
6. Song A, Nikolcheva T, Krensky AM. Transcriptional regulation of RANTES expression in T lymphocytes. Immunol Rev 2000; 177: 236-245.
7. + cells. Eur J Immunol 1996; 26: 315-319. (Pubitemid 26060235)
8. + T cells. Science 1995; 270: 1811-1815.
9. Pakianathan DR, Kuta EG, Artis DR, Skelton NJ, Hebert CA. Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. Biochemistry 1997; 36: 9642-9648. (Pubitemid 27364674)
10. Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J2004; 25: 1438-1446. (Pubitemid 39078251)
11. Gade-Andavolu R, Comings DE, MacMurray J, Vuthoori RK, Tourtellotte WW, Nagra RM et al. RANTES: a genetic risk markerfor multiplesclerosis. Mult Scler 2004; 10: 536-539. (Pubitemid 39207227)
12. Wang CR, Guo HR, Liu MF. RANTES promoter polymorphism as a genetic risk factor for rheumatoid arthritis in the Chinese. Clin Exp Rheumatol 2005; 23: 379-384.
13. Makki RF, Al Sharif F, Gonzalez-Gay MA, Garcia-Porrua C, Ollier WE, Hajeer AH. RANTESgene polymorphism in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis. Clin Exp Rheumatol 2000; 18: 391-393. (Pubitemid 30409112)
14. Fryer AA, Spiteri MA, Bianco A, Hepple M, Jones PW, Strange RC et al. The-403 G→A promoter polymorphism in the RANTES gene is associatedwithatopyandasthma. Genes Immun 2000; 1: 509-514.
15. Al-Abdulhadi SA, Helms PJ, Main M, Smith O, Christie G. Preferential transmission and association of the-403 G→A promoter RANTES polymorphism with atopic asthma. Genes Immun 2005; 6: 24-30. (Pubitemid 40260130)
16. Yao TC, Kuo ML, See LC, Chen LC, Yan DC, Ou LS et al. The RANTES promoter polymorphism: a genetic risk factor for near-fatal asthma in Chinesechildren. JAllergy Clin Immunol 2003; 111: 1285-1292.
17. Hizawa N, Yamaguchi E, Konno S, Tanino Y, Jinushi E, Nishimura M. A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma. Am J Respir Crit Care Med 2002; 166: 686-690. (Pubitemid 34971851)
18. Kozma GT, Falus A, Bojszko A, Krikovszky D, Szabo T, Nagy A et al. Lack of association between atopic eczema/dermatitis syndrome and polymorphisms in the promoter region of RANTES and regulatory region of MCP-1. Allergy 2002; 57: 160-163. (Pubitemid 34538897)
19. Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCVinfection. Hepatology 2003; 38: 1468-1476. (Pubitemid 37466973)
20. Promrat K, Liang TJ. Chemokine systems and hepatitis C virus infection: is truth in the genes of the beholders? Hepatology 2003; 38: 1359-1362. (Pubitemid 37466960)
21. Simeoni E, Vassalli G, Seydoux C, Ramsay D, Noll G, von Segesser LK et al. CCR5, RANTES and CX3CR1 polymorphisms: possible genetic links with acute heart rejection. Transplantation 2005; 80: 1309-1315. (Pubitemid 41746810)
22. Liao CH, Yao TC, Chung HT, See LC, Kuo ML, Huang JL. Polymorphisms in the promoter region of RANTES and the regulatory region of monocyte chemoattractant protein-1 among Chinese children with systemic lupus erythematosus. J Rheumatol 2004; 31: 2062-2067.
23. Ye DQ, Yang SG, Li XP, Hu YS, Yin J, Zhang GQ et al. Polymorphismsin the promoterregionof RANTES in Han Chineseandtheirrelationship with systemic lupus erythematosus. Arch Dermatol Res 2005; 297: 108-113. (Pubitemid 41425040)
24. Donlon TA, Krensky AM, Wallace MR, Collins FS, Lovett M, Clayberger C. Localization of a human T-cell-specific gene, RANTES (D17S136E), to chromosome 17q11. 2-q12. Genomics 1990; 6: 548-553. (Pubitemid 20168688)
25. Gu M, Ghafari S, Zhao M. Fluorescence insitu hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsyspecimens. Acta Cytol 2005; 49: 471-476. (Pubitemid 41331075)
26. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M et al. The CCchemokine RANTES in breastcarcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002; 62: 1093-1102. (Pubitemid 34160293)
27. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissueand plasma RANTES levelswith diseasecourse in patientswith breastorcervicalcancer. Clin Cancer Res 2001; 7: 285-289.
28. Nouh MA, Eissa SA, Zaki SA, El-Maghraby SM, Kadry DY. Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Canc Inst 2005; 17: 51-55.
29. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004; 10: 6789-6795. (Pubitemid 39383027)
30. Wigler N, Shina S, Kaplan O, Luboshits G, Chaitchik S, Keydar I et al. Breast carcinoma: a report on the potential usage of the CC chemokine RANTES asa markerfora progressive disease. Isr Med Assoc J2002; 4: 940-943. (Pubitemid 35291276)
31. Sauer G, Schneiderhan-Marra N, Kazmaier C, Hutzel K, Koretz K, Muche R et al. Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin Cancer Res 2008; 14: 3345-3353.
32. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999; 59: 4681-4687. (Pubitemid 29428976)
33. Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E et al. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 2006; 12: 4474-4480. (Pubitemid 44297794)
34. Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L et al. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 2008;44: 191-200.
35. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T et al. Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011; 11: 130.
36. Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 2004; 109: 507-515. (Pubitemid 38339640)
37. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 2000; 19: 1002-1009. (Pubitemid 30153783)
38. Perou CM, Sorlie T, Eisen MB, vandeRijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
39. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98: 10869-10874. (Pubitemid 32878711)
40. Irvin WJ, Jr., Carey LA. What is triple-negative breast cancer? Eur J Cancer 2008; 44: 2799-2805.
41. Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A et al. Basal cytokeratinand epidermal growth factor receptorexpression are not predictive of BRCA1 mutation status in women with triple-negative breastcancers. Am JSurg Pathol 2009; 33: 1093-1097.
42. Iglehart JD, Silver DP. Synthetic lethality-a newdirection incancer-drugdevelopment. N Engl J Med 2009; 361: 189-191.
43. Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 1983; 33: 22-31. (Pubitemid 13083351)
44. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7. 1 cell-based tumor vaccines. Cancer Res 1998; 58: 1486-1493. (Pubitemid 28193612)
45. Mi Z, Guo H, Wai PY, Gao C, Wei J, Kuo PC Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior. J Biol Chem 2004; 279: 46659-46667. (Pubitemid 39518312)
46. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-1405.
47. Morecki S, Yacovlev L, Slavin S. Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma. Int JCancer 1998; 75:894-899. (Pubitemid 28134115)
48. Ostrand-Rosenberg S, Grusby MJ, Clements VK. Cuttingedge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol 2000; 165: 6015-6019.
49. Coveney E, Wheatley GH 3rd, Lyerly HK. Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breastcancer. Surgery 1997; 122: 228-234. (Pubitemid 27383060)
50. Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang NS. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases viaa T-cell-independent mechanism. Cancer Gene Ther 2000; 7: 826-838. (Pubitemid 30437282)
51. Shi X, Cao S, Mitsuhashi M, Xiang Z, Ma X. Genome-wide analysisof molecularchanges in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanisms. J Immunol 2004; 172: 4111-4122. (Pubitemid 38375223)
52. + tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol Immunother 2000; 49: 34-45. (Pubitemid 30430677)
53. Christensen CR, Klingelhofer J, Tarabykina S, Hulgaard EF, Kramerov D, Lukanidin E. Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines. Cancer Res 1998; 58: 1238-1244. (Pubitemid 28183214)
54. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998; 95: 8829-8834. (Pubitemid 28350574)
55. Wang H, Mohammad RM, Werdell J, Shekhar PV. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: in vitroversus in vivoactivity. Int J Mol Med 1998; 1: 915-923.
56. Morecki S, Yacovlev E, Gelfand Y, Trembovler V, Shohami E, Slavin S. Induction of antitumor immunity by indomethacin. Cancer Immunol Immunother 2000; 48: 613-620. (Pubitemid 30064663)
57. Adler EP, Lemken CA, Katchen NS, Kurt RA. A dual role fortumor-derived chemokine RANTES (CCL5). Immunol Lett 2003; 90: 187-194. (Pubitemid 37548476)
58. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003; 63: 8360-8365. (Pubitemid 37549490)
59. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008; 267: 271-285.
60. Kurt RA, Baher A, Wisner KP, Tackitt S, Urba WJ. Chemokinereceptor desensitization intumor-bearingmice. Cell Immunol 2001; 207:81-88.
61. Liu J, Guan X, Ma X. Interferonregulatoryfactor1 isanessentialand directtranscriptionalactivatorforinterferonγ-induced RANTES/CCl5 expression in macrophages. JBiol Chem 2005; 280: 24347-24355.
62. Ma X, Chow JM, Gri G, Carra G, Gerosa F, Wolf SF et al. Theinterleukin 12p40gene promoter is primed by interferon gamma in monocytic cells. J Exp Med 1996; 183: 147-157. (Pubitemid 26028754)
63. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-kappaB in hematologic malignancies. Cell Death Differ 2006; 13: 748-758.
64. Liu J, Cao S, Herman LM, Ma X. Differential regulation of interleukin (IL)-12p35and p40gene expression and interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1. JExp Med 2003; 198: 1265-1276. (Pubitemid 37323391)
65. Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, Vinson C. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem 1997; 272: 18586-18594. (Pubitemid 27318198)
66. Ammit AJ, Hoffman RK, Amrani Y, Lazaar AL, Hay DW, Torphy TJ et al. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells. Modulation by cyclic adenosine monophosphate. Am J Respir Cell Mol Biol 2000; 23: 794-802. (Pubitemid 32013272)
67. 2-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells. Br J Pharmacol 2001; 132: 729-741. (Pubitemid 32165189)
68. Ammit AJ, Lazaar AL, Irani C, O'Neill GM, Gordon ND, Amrani Y et al. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. Am J Respir Cell Mol Biol 2002; 26: 465-474. (Pubitemid 34253931)
69. Ahn S, Olive M, Aggarwal S, Krylov D, Ginty DD, Vinson C. Adominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos. Mol Cell Biol 1998; 18: 967-977. (Pubitemid 28063431)
70. Mrowietz U, Schwenk U, Maune S, Bartels J, Kupper M, Fichtner I et al. Thechemokine RANTES issecreted by human melanomacellsand is associated with enhanced tumour formation in nude mice. Br J Cancer 1999;79: 1025-1031. (Pubitemid 29087870)
71. Fischer M, Juremalm M, Olsson N, Backlin C, Sundstrom C, Nilsson K et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatoustissue. Int JCancer 2003; 107: 197-201. (Pubitemid 37152897)
72. Mori N, Krensky AM, Ohshima K, Tomita M, Matsuda T, Ohta T et al. Elevated expression of CCL5/RANTES in adult T-cell leukemia cells: possible transactivation of the CCL5gene by human T-cell leukemia virustype I tax. Int JCancer 2004; 111: 548-557. (Pubitemid 39045322)
73. Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitativeassessment of the leukocyte infiltrate in ovarian cancerand its relationship to the expressionofC-Cchemokines. Am JPathol 1997; 150: 1723-1734. (Pubitemid 27193819)
74. Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 2004; 171: 2171-2175. (Pubitemid 38625428)
75. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006; 66: 124-134. (Pubitemid 43191234)
76. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecol Oncol 2006; 102: 542-545. (Pubitemid 44353649)
77. Ek S, Bjorck E, Hogerkorp CM, Nordenskjold M, Porwit-Mac Donald A, Borrebaeck CA. Mantlecell lymphomasacquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer 2006; 118: 2092-2097.
78. Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE et al. RANTES expression isa predictorof survival in stage I lung adenocarcinoma. Clin Cancer Res 2002; 8: 3803-3812. (Pubitemid 35424773)
79. Jayasinghe MM, Golden JM, Nair P, O'Donnell CM, Werner MT, Kurt RA. Tumor-derived CCL5 does not contribute to breast cancer progression. Breast Cancer Res Treat 2008; 111: 511-521.
80. Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother 2006; 55: 734-743.
81. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
82. Seung LP, Rowley DA, Dubey P, Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 1995; 92: 6254-6258.
83. + T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999; 162: 5728-5737. (Pubitemid 29314923)
84. Salvadori S, Martinelli G, Zier K. Resection ofsolidtumorsreversesT cell defectsandrestoresprotective immunity. JImmunol 2000; 164: 2214-2220. (Pubitemid 30108782)
85. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741-1752. (Pubitemid 37494166)
86. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004; 64: 2205-2211. (Pubitemid 38339474)
87. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16: 53-65. (Pubitemid 43139709)
88. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008; 267: 271-285.
89. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003; 22: 256-265. (Pubitemid 36174182)
90. Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, O'Sullivan MP et al. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med 2005; 11: 1180-1187. (Pubitemid 43093665)
91. Machado FS, Koyama NS, Carregaro V, Ferreira BR, Milanezi CM, Teixeira MM et al. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J Infect Dis 2005; 191: 627-636. (Pubitemid 40216680)
92. Campbell LD, Stewart JN, Mead JR. Susceptibilityto Cryptosporidium parvum infections in cytokine-and chemokine-receptor knockout mice. JParasitol 2002; 88: 1014-1016. (Pubitemid 35278754)
93. Algood HM, Flynn JL. CCR5-deficient mice control Mycobacterium tuberculosis infection despite increased pulmonary lymphocytic infiltration. JImmunol 2004; 173: 3287-3296. (Pubitemid 39142037)
94. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R et al. Geneticrestrictionof HIV-1 infectionand progressiontoAIDS by adeletionalleleof theCKR5structural gene. Hemophilia Growthand Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-1862.